Azurity Pharmaceuticals has issued a recall for the widely-used Attention Deficit Hyperactivity Disorder (ADHD) medication, Zenzedi, after a mix-up was discovered in the packaging. A pharmacist in Nebraska found Carbinoxamine Maleate, an antihistamine, mixed with the 30-milligram dextroamphetamine sulfate tablets. The recall, prompted by the Food and Drug Administration (FDA), affects the specific lot F230169A, set to expire in June 2025. Dextroamphetamine sulfate is a stimulant, while Carbinoxamine Maleate has sedative effects. Patients mistakenly taking the antihistamine instead of Zenzedi could experience undertreatment, leading to functional impairment and an increased risk of accidents or injury. Adverse effects may include drowsiness, sleepiness, central nervous system depression, increased eye pressure, enlarged prostate urinary obstruction, and thyroid disorder. Individuals diagnosed with ADHD or narcolepsy face a “reasonable probability” of ongoing disability or death from accidents or injuries during activities requiring focus and alertness. This recall comes amid an existing shortage of common ADHD medications like Adderall in the country.
